These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 8433020

  • 21. Cytotoxicity of mitomycin C and carboquone combined with hyperthermia against hypoxic tumor cells in vitro.
    Sakaguchi Y, Kohnoe S, Emi Y, Maehara Y, Kusumoto T, Sugimachi K.
    Oncology; 1992; 49(3):227-32. PubMed ID: 1495751
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Rate-limiting steps in the interactions of fluoropyrimidines and methotrexate.
    Bowen D, Bailey BD, Guernsey LA.
    Eur J Cancer Clin Oncol; 1984 May; 20(5):651-7. PubMed ID: 6234172
    [Abstract] [Full Text] [Related]

  • 24. Formation of conjugates of 2-fluoro-beta-alanine and bile acids during the metabolism of 5-fluorouracil and 5-fluoro-2-deoxyuridine in the isolated perfused rat liver.
    Sweeny DJ, Barnes S, Diasio RB.
    Cancer Res; 1988 Apr 15; 48(8):2010-4. PubMed ID: 2964897
    [Abstract] [Full Text] [Related]

  • 25. Reduced cellular transport and activation of fluoropyrimidine nucleosides and resistance in human lymphocytic cell lines selected for arabinosylcytosine resistance.
    Agarwal RP, Han T, Fernandez M.
    Biochem Pharmacol; 2001 Jan 01; 61(1):39-47. PubMed ID: 11137707
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Changes in thymidylate synthase and its inhibition rate and changes in dihydropyrimidine dehydrogenase after the administration of 5-fluorouracil with cisplatin to nude mice with gastric cancer xenograft SC-1-NU.
    Sakurai Y, Uraguchi T, Imazu H, Hasegawa S, Matsubara T, Ochiai M, Funabiki T.
    Gastric Cancer; 2004 Jan 01; 7(2):110-6. PubMed ID: 15224198
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Enhanced therapeutic efficacy of 5'deoxy-5-fluorouridine in 5-fluorouracil resistant head and neck tumours in relation to 5-fluorouracil metabolising enzymes.
    Peters GJ, Braakhuis BJ, de Bruijn EA, Laurensse EJ, van Walsum M, Pinedo HM.
    Br J Cancer; 1989 Mar 01; 59(3):327-34. PubMed ID: 2522792
    [Abstract] [Full Text] [Related]

  • 34. Relationship between antitumor effect and metabolites of 5-fluorouracil in combination treatment with 5-fluorouracil and guanosine in ascites sarcoma 180 tumor system.
    Iigo M, Kuretani K, Hoshi A.
    Cancer Res; 1983 Dec 01; 43(12 Pt 1):5687-94. PubMed ID: 6640523
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Distinguishing between membrane transport and intracellular metabolism of fluorodeoxyuridine in Ehrlich ascites tumor cells by application of kinetic and high performance liquid chromatographic techniques.
    Bowen D, Diasio RB, Goldman ID.
    J Biol Chem; 1979 Jun 25; 254(12):5333-9. PubMed ID: 156181
    [No Abstract] [Full Text] [Related]

  • 38. Sequential methotrexate/5-FU: FdUMP formation and TS inhibition in a transplantable rodent colon adenocarcinoma.
    Berne MH, Gustavsson BG, Almersjö O, Spears PC, Frösing R.
    Cancer Chemother Pharmacol; 1986 Jun 25; 16(3):237-42. PubMed ID: 3698165
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.